Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities.
However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Wednesday as we examine the latest happenings in today's session.
Curious about the top performers within the S&P500 index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Looking for the S&P500 stocks that are experiencing notable gaps on Wednesday? Find out which stocks are gapping up and gapping down in the S&P500 index during today's session.
A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides agreed to pause some tariffs for 90 days, signaling a potential turning point in ongoing tensions. This rollback cuts U.S. tariffs on Chinese goods to 30% and Chinese tariffs on U.S. imports to 10%, giving companies breathing room to reset inventories and supply chains.
Life sciences company Revvity (NYSE:RVTY) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 2.3% year on year to $664.8 million. The company’s full-year revenue guidance of $2.85 billion at the midpoint came in 0.6% above analysts’ estimates. Its non-GAAP profit of $1.01 per share was 6.4% above analysts’ consensus estimates.
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
For the full year, Revvity raised its revenue guidance to a range of $2.83 billion to $2.87 billion to reflect recent changes in foreign currency exchange rates.
Life sciences company Revvity (NYSE:RVTY) announced better-than-expected revenue in Q1 CY2025, with sales up 2.3% year on year to $664.8 million. The company’s full-year revenue guidance of $2.85 billion at the midpoint came in 0.6% above analysts’ estimates. Its non-GAAP profit of $1.01 per share was 6.4% above analysts’ consensus estimates.
The Board of Directors of Revvity (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 8, 2025 to all shareholders of record at the close of business on July 18, 2025.
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Revvity, Inc. (NYSE: RVTY), today announced that it will release its first quarter 2025 financial results prior to market open on Monday, April 28, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call.
Revvity's stock rose after FDA approval of its Auto-Pure 2400 platform integrated with the T-SPOT.TB test, improving latent TB detection efficiency in labs.
Revvity, Inc. (NYSE: RVTY), today announced that the U.S. Food and Drug Administration (FDA) has approved the Auto-Pure 2400 liquid handling platform with the T-SPOT™.TB test. Initially launched outside the U.S. in 2024, this powerful combination allows laboratories to improve productivity while maintaining superior clinical performance in latent tuberculosis (TB) detection. This milestone marks a significant advancement in the fight against TB with a faster high-throughput solution delivering accurate diagnostic results to support timely treatment and containment in the U.S. as well as other locations around the world.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns -
over the past six months, healthcare stocks have collectively shed 11.1%. This drop was worse than the S&P 500’s 4% decline.
